Turku PET Centre provides vartiety of research services for pharma.
These include radiotracer development and testing services and preclinical and clinical Phase I-VI imaging studies. Turku PET Centre has been collaborating with all major pharma during the last 20 years and performed numerous research projects. We comply with the quality requirements of pharma (GMP, GLP, GCP) when applicable. Turku PET Centre has a partnership contract with Turku Imanet which an affiliate of GE Healthcare.
The services can include not only PET studies but also CT, MRI (1.5T and 3.0T), PET/CT and PET/MRI and ultrasound studies. The investigator have access to various animal models for human diseases. The most commonly used are mouse, rat, rabbit and pig models. The preclinical services include also in vitro, ex vivo and in vivo imaging.
The clinical projects are done in partnership with Clinical Reserach Services Turku (CRST) which is an CRO owned by University of Turku. See more information about CRST at www.crst.fi
Examples of recent Phase I-III clinical studies at Turku PET Centre:
Occupancy study of antidepressant target in the brain of healthy volunteers – provided important guidance for dose level selection in Phase II trials and helped to reach a no-go decision before Phase III (Bergström M et al., Biol Psychiatry 2004, 55:1007-12)
The study investigating the effects of 12-month enzyme replacement therapy on myocardial perfusion in patients with Fabry disease. (Kalliokoski RJ et al. J Inherit Metab Dis. 2006 Feb;29(1):112-8.)
Investigation of the estradiol-drospirenone hormone treatment on myocardial perfusion reserve in postmenopausal women with angina pectoris. (Knuuti J, et al. Am J Cardiol. 2007 Jun 15;99(12):1648-52.)
A 16-week randomized, double-blind, placebo-controlled study of Rosiglitazone on myocardial glucose uptake in patients with type 2 diabetes and coronary artery disease. (Lautamäki R, et al Diabetes. 2005 Sep;54(9):2787-94.)
Occupancy study of therapeutic target in the brain of Alzheimer’s patients and healthy control subjects – provided important information for Phase II dose selection (Hirvonen J et al., Clin Pharmacol Ther 2009, 85:506-12)
Amyloid imaging study to assess efficacy of anti-amyloid therapy in Alzheimer’s disease – suggested that the treatment has anti-amyloid efficacy and that [11C]-PiB PET imaging is useful in assessing the effects of potential anti-amyloid treatments in Alzheimer’s disease (Rinne JO et al., Lancet Neurol 2010, 9:363-72)